Professional Documents
Culture Documents
interferon-beta-1b
Therapeutic proteins continuously acquire higher shares of the pharmaceuticals market. Monoclonal antibodies, for example, show doubledigit growth rates and also proteins which have been known for a longer period of time, such as interferon- (IFN-) exhibit an annual turnover
of three billion US dollars. Treatment with IFN- is one of the current basic therapies for the most frequent form of multiple sclerosis (MS),
relapsing-remitting MS. The costs for IFN- treatment in Germany amount to 18,000 euros per patient and year with the consequence that the
majority of the 2.5 million MS patients worldwide cannot be adequately treated with IFN-. In this context, the required quantities of active
substances at 45 mg per patient and year for IFN--1b are very small.
1/3
Perspective
With the technically simple and scalable purification process for IFN--1b established at the Fraunhofer IGB, the majority of the bacterial
proteins are separated directly in the first purification step. We can thus avoid the laborious isolation, purification and solubilization of the
inclusion bodies, which result in high losses. This process supplies IFN--1b in high purity, which can be reasonably manufactured on an
industrial scale.
Project partners
Cinnagen, Teheran, Iran
www.igb.fraunhofer.de/en/competences/molecular-biotechnology//purification-interferon-beta.html
2/3
Contact
Fraunhofer-Gesellschaft
Source: Fraunhofer-Gesellschaft: Fraunhofer Institute for Interfacial Engineering and Biotechnology - Extraction and
purification process for interferon-beta-1b
Online in the Web ; URLhttp://www.igb.fraunhofer.de/en/competences/molecular-biotechnology/therapeutic-proteins/purificationinterferon-beta.html
[Date: 24.06.2013, 14:41 hour]]
www.igb.fraunhofer.de/en/competences/molecular-biotechnology//purification-interferon-beta.html
3/3